Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL28081742 | 0.98 | TDP1 (0.46) | TDP1LMNAALDH1A1MAPK1HSD17B10 | |
| Glycerin SCHEMBL4594676 | 0.96 | TDP1 (0.48) | TDP1LMNAALDH1A1MAPK1HSD17B10 | |
| Glycerin SCHEMBL28367056 | 0.94 | TDP1 (0.42) | TDP1LMNAALDH1A1MAPK1HSD17B10 | |
| SCHEMBL23248659 | 0.93 | — | — | |
| SCHEMBL16542024 | 0.93 | — | — | |
| SCHEMBL8747551 | 0.93 | — | — | |
| SCHEMBL23248656 | 0.93 | — | — | |
| SCHEMBL15111 | 0.93 | — | — | |
| SCHEMBL7612087 | 0.93 | TDP1 (0.52) | TDP1LMNAALDH1A1MAPK1HSD17B10 | |
| Methyl Alcohol SCHEMBL6033793 | 0.90 | TDP1 (0.50) | TDP1LMNAALDH1A1MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106414626-B | Ink composition | 惠普发展公司，有限责任合伙企业 | 2020-10-23 | — | — | CN | claimed |
| CN-111494291-A | Blue light resisting and aging delaying skin care cosmetic and preparation method thereof | 珠海越美科技有限公司 | 2020-08-07 | — | — | CN | claimed |
| CN-111095609-A | Laser ablation for manufacturing battery cells | 戴森技术有限公司 | 2020-05-01 | — | — | CN | claimed |
| EP-3292191-B1 | ALKALINE DISHWASH COMPOSITION | UNILEVER NV (NL) | 2019-06-05 | — | — | EP | claimed |
| EP-3292191-A1 | ALKALINE DISHWASH COMPOSITION | Unilever N.V. (NL) | 2018-03-14 | — | — | EP | claimed |
| WO-2016177563-A1 | ALKALINE DISHWASH COMPOSITION | UNILEVER N.V. (NL) | 2016-11-10 | — | — | WO | claimed |
| US-20240018085-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | BIOJIVA LLC | 2024-01-18 | — | — | US | disclosed |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | BIOJIVA LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RTMFP ENTERPRISES INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | BIOJIVA LLC | 2022-05-05 | — | — | US | disclosed |
| EP-3950649-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1, 4-DIENE SYSTEMS | Retrotope, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | RETROTOPE, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3943081-A1 | OPTIC NEUROPATHY TREATMENT AND REDUCTION OF STEROID- INDUCED OXIDATIVE STRESS WITH STABILIZED POLYUNSATURATED SUBSTANCES | Retrotope, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20050019379-A1 | Promotes adherence of Lactobacillus acidophilus to skin surface or mucosa; wet wipes, absorbents; Ginseng, glucosamine, and Yucca; inhibiting growth of Candida, Proteus, Pseudomonas, and/or Staphlococcus | KIMBERLY-CLARK WORLDWIDE, INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004045575-A1 | ANTIOXIDANT-CONTAINING WIPES AND ABSORBENT PRODUCTS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040096484-A1 | Antioxidant-containing wipes and absorbent products for improving skin health | KIMBERLY-CLARK WORLDWIDE, INC. | 2004-05-20 | — | — | US | disclosed |
| US-20040024233-A1 | Fatty acid esters composition of a polyglycerine, a process for the preparation thereof, a process for the preparation of a highly-purified fatty acid esters composition of a polyglycerine, a highly-purified fatty acid esters composition of a polyglycerine, an additive for food-stuffs, a resin composition, and a composition for cosmetics or detergents | ENDO TOSHIO (JP) | 2004-02-05 | — | — | US | disclosed |
| CN-1210549-A | Preparation of double metal cyanide-catalyzed polyols by continuous addition of starter | ARCO CHEM TECH (US) | 1999-03-10 | — | — | CN | disclosed |
| CN-1014955-B | Cosmetic preparation | KAO CORP (JP) | 1991-12-04 | — | — | CN | disclosed |
| CN-88100344-A | Cosmetics | — | 1988-08-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018085-A1 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | FADS1, FASN, FADS2 | TDP1 2860/4885LMNA 2040/4885ALDH1A1 832/4885 |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | CPT1B, PSEN2, NLN | TDP1 634/4885LMNA 637/4885ALDH1A1 2738/4885 |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | CPT1B, PSEN2, NLN | TDP1 634/4885LMNA 637/4885ALDH1A1 2738/4885 |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | GPX4, CPT1A, FABP1 | TDP1 3724/4885LMNA 806/4885ALDH1A1 298/4885 |
| US-20040024233-A1 | Fatty acid esters composition of a polyglycerine, a process for the preparation thereof, a process for the preparation of a highly-purified fatty acid esters composition of a polyglycerine, a highly-purified fatty acid esters composition of a polyglycerine, an additive for food-stuffs, a resin composition, and a composition for cosmetics or detergents | FASN, DGAT2, SCD5 | TDP1 2812/4885LMNA 2832/4885ALDH1A1 731/4885 |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | ACADM, CPT1A, ALDH2 | TDP1 3890/4885LMNA 1125/4885ALDH1A1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.